Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | REN | P00797 | 2/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | USP2 | O75604 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | MMP9 | P14780 | 1/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | DAO | P14920 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1229722 | 0.92 | ALDH1A1 (0.30) | ALDH1A1 | |
| SCHEMBL1228551 | 0.81 | REN (0.33) | RENCYP3A4KCNH2KDM4EUSP2 | |
| SCHEMBL11942310 | 0.81 | REN (0.37) | RENCYP3A4KCNH2KDM4EALDH1A1 | |
| SCHEMBL1229578 | 0.76 | SHBG (0.40) | RENCYP3A4KCNH2DAO | |
| SCHEMBL1228024 | 0.73 | KCNH2 (0.41) | RENKCNH2 | |
| SCHEMBL1518881 | 0.72 | KDM4E (0.38) | RENCYP3A4KCNH2KDM4EALDH1A1 | |
| SCHEMBL11942309 | 0.71 | TAS1R3 (0.34) | RENKDM4EALDH1A1 | |
| SCHEMBL15262553 | 0.70 | ALDH1A1 (0.45) | KDM4EUSP2ALDH1A1LMNAMMP9 | |
| SCHEMBL30173751 | 0.67 | KDM4E (0.50) | KDM4EUSP2ALDH1A1LMNAMMP9 | |
| SCHEMBL1228162 | 0.67 | ALDH1A1 (0.39) | KDM4EALDH1A1LMNAALOX15TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120190701-A1 | RENIN INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2012-07-26 | — | — | US | disclosed |
| EP-2467385-A1 | RENIN INHIBITORS | Merck Canada Inc. (CA) | 2012-06-27 | — | — | EP | disclosed |
| WO-2011020193-A1 | RENIN INHIBITORS | MERCK FROSST CANADA LTD. (CA) | 2011-02-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120190701-A1 | RENIN INHIBITORS | REN, ACE, AGTR1 | REN 1/4885CYP3A4 908/4885KCNH2 35/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.